CONTEXT: Telomeres are essential to preserve the integrity of the genome. Critically short telomeres lead to replicative cell senescence and chromosomal instability and may thereby increase cancer risk. OBJECTIVE: To determine the association between baseline telomere length and incident cancer and cancer mortality. DESIGN, SETTING, AND PARTICIPANTS: Leukocyte telomere length was measured by quantitative polymerase chain reaction in 787 participants free of cancer at baseline in 1995 from the prospective, population-based Bruneck Study in Italy. MAIN OUTCOME MEASURES: Incident cancer and cancer mortality over a follow-up period of 10 years (1995-2005 with a follow-up rate of 100%). RESULTS: A total of 92 of 787 participants (11.7%) developed cancer (incidence rate, 13.3 per 1000 person-years). Short telomere length at baseline was associated with incident cancer independently of standard cancer risk factors (multivariable hazard ratio [HR] per 1-SD decrease in log(e)-transformed telomere length, 1.60; 95% confidence interval [CI], 1.30-1.98; P < .001). Compared with participants in the longest telomere length group, the multivariable HR for incident cancer was 2.15 (95% CI, 1.12-4.14) in the middle length group and 3.11 (95% CI, 1.65-5.84) in the shortest length group (P < .001). Incidence rates were 5.1 (95% CI, 2.9-8.7) per 1000 person-years in the longest telomere length group, 14.2 (95% CI, 10.0-20.1) per 1000 person-years in the middle length group, and 22.5 (95% CI, 16.9-29.9) per 1000 person-years in the shortest length group. The association equally applied to men and women and emerged as robust under a variety of circumstances. Furthermore, short telomere length was associated with cancer mortality (multivariable HR per 1-SD decrease in log(e)-transformed telomere length, 2.13; 95% CI, 1.58-2.86; P < .001) and individual cancer subtypes with a high fatality rate. CONCLUSION: In this study population, there was a statistically significant inverse relationship between telomere length and both cancer incidence and mortality.
CONTEXT: Telomeres are essential to preserve the integrity of the genome. Critically short telomeres lead to replicative cell senescence and chromosomal instability and may thereby increase cancer risk. OBJECTIVE: To determine the association between baseline telomere length and incident cancer and cancer mortality. DESIGN, SETTING, AND PARTICIPANTS: Leukocyte telomere length was measured by quantitative polymerase chain reaction in 787 participants free of cancer at baseline in 1995 from the prospective, population-based Bruneck Study in Italy. MAIN OUTCOME MEASURES: Incident cancer and cancer mortality over a follow-up period of 10 years (1995-2005 with a follow-up rate of 100%). RESULTS: A total of 92 of 787 participants (11.7%) developed cancer (incidence rate, 13.3 per 1000 person-years). Short telomere length at baseline was associated with incident cancer independently of standard cancer risk factors (multivariable hazard ratio [HR] per 1-SD decrease in log(e)-transformed telomere length, 1.60; 95% confidence interval [CI], 1.30-1.98; P < .001). Compared with participants in the longest telomere length group, the multivariable HR for incident cancer was 2.15 (95% CI, 1.12-4.14) in the middle length group and 3.11 (95% CI, 1.65-5.84) in the shortest length group (P < .001). Incidence rates were 5.1 (95% CI, 2.9-8.7) per 1000 person-years in the longest telomere length group, 14.2 (95% CI, 10.0-20.1) per 1000 person-years in the middle length group, and 22.5 (95% CI, 16.9-29.9) per 1000 person-years in the shortest length group. The association equally applied to men and women and emerged as robust under a variety of circumstances. Furthermore, short telomere length was associated with cancer mortality (multivariable HR per 1-SD decrease in log(e)-transformed telomere length, 2.13; 95% CI, 1.58-2.86; P < .001) and individual cancer subtypes with a high fatality rate. CONCLUSION: In this study population, there was a statistically significant inverse relationship between telomere length and both cancer incidence and mortality.
Authors: Aoife O'Donovan; A Janet Tomiyama; Jue Lin; Eli Puterman; Nancy E Adler; Margaret Kemeny; Owen M Wolkowitz; Elizabeth H Blackburn; Elissa S Epel Journal: Brain Behav Immun Date: 2012-01-24 Impact factor: 7.217
Authors: Mengmeng Du; Jennifer Prescott; Peter Kraft; Jiali Han; Edward Giovannucci; Susan E Hankinson; Immaculata De Vivo Journal: Am J Epidemiol Date: 2012-02-01 Impact factor: 4.897
Authors: R T Calado; J N Cooper; H M Padilla-Nash; E M Sloand; C O Wu; P Scheinberg; T Ried; N S Young Journal: Leukemia Date: 2011-10-18 Impact factor: 11.528
Authors: Jian-Min Yuan; Kenneth B Beckman; Renwei Wang; Caroline Bull; Jennifer Adams-Haduch; Joyce Y Huang; Aizhen Jin; Patricia Opresko; Anne B Newman; Yun-Ling Zheng; Michael Fenech; Woon-Puay Koh Journal: Int J Cancer Date: 2018-01-25 Impact factor: 7.396
Authors: Lauren M Hurwitz; Christopher M Heaphy; Corinne E Joshu; William B Isaacs; Yuko Konishi; Angelo M De Marzo; Sally D Isaacs; Kathy E Wiley; Elizabeth A Platz; Alan K Meeker Journal: Prostate Date: 2013-11-28 Impact factor: 4.104
Authors: Halcyon G Skinner; Ronald E Gangnon; Kristin Litzelman; Ruth A Johnson; Suresh T Chari; Gloria M Petersen; Lisa A Boardman Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-10-23 Impact factor: 4.254